rss
J Med Genet 2008;45:268-274 doi:10.1136/jmg.2007.055319
  • Original article

Comparison of targeted and whole genome analysis of postnatal specimens using a commercially available array based comparative genomic hybridisation (aCGH) microarray platform

  1. E Aston1,
  2. H Whitby1,
  3. T Maxwell1,
  4. N Glaus1,
  5. B Cowley1,4,
  6. D Lowry1,
  7. X L Zhu1,
  8. B Issa1,
  9. S T South1,3,
  10. A R Brothman1,2,3
  1. 1
    University of Utah CGH Microarray Laboratory, Department of Pediatrics, Salt Lake City, Utah, USA
  2. 2
    University of Utah Department of Human Genetics, Salt Lake City, Utah, USA
  3. 3
    University of Utah Department of Pathology, Salt Lake City, Utah, USA
  4. 4
    IVF Genetics LLC, Salt Lake City, Utah, USA
  1. Dr A R Brothman, University of Utah CGH Microarray Laboratory, SOM 1C210, 30N 1900 E, Salt Lake City, UT 84132, USA; art.brothman{at}genetics.utah.edu
  • Received 10 October 2007
  • Revised 4 December 2007
  • Accepted 7 December 2007
  • Published Online First 4 January 2008

Abstract

Purpose: The University of Utah Comparative Genomic Hybridization Microarray Laboratory was one of the first US laboratories to offer comparative genomic hybridisation (CGH) microarray testing using a commercial platform in a clinical setting. Results for 1076 patients (1598 chips) are presented.

Methods: The Spectral Genomics/PerkinElmer Constitutional ChipTM (targeted array), SpectralChip 2600TM (whole genome array) and a “Combo” chip (both arrays run simultaneously) were the tests offered. Abnormal results were confirmed by an alternative method, most often fluorescence in situ hybridisation.

Results: In 669 cases with known normal cytogenetics, an abnormal detection rate of 10.8% was observed, (5.3%, 12.2% and 14.1% for the Constitutional ChipTM, SpectralChip 2600TM and Combo assay, respectively). Known copy number variants and single clone abnormalities are not included in these rates. Single clone abnormalities are reported separately. For 1076 total cases, we report an average abnormal rate of 16.9% (8.7%, 23.7% and 18.6% for the three assays). This rate includes characterisation of some abnormalities previously identified by cytogenetics.

Conclusions: CGH microarray provides a likely aetiology for the clinical phenotype in many cytogenetically normal cases, and a whole genome array generally identifies copy number changes more effectively than a targeted chip alone.

Footnotes

  • Competing interests: None declared.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. web only table

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.